Abstract
Elderly people are more likely than younger patients to develop cognitive impairment as a result of taking medications. This reflects age- and disease-associated changes in brain neurochemistry and drug handling. Delirium (acute confusional state) is the cognitive disturbance most clearly associated with drug toxicity, but dementia has also been reported. The aetiology of cognitive impairment is commonly multifactorial, and it may be difficult to firmly establish a causal role for an individual medication.
In studies of elderly hospital patients, drugs have been reported as the cause of delirium in 11 to 30% of cases. Medication toxicity occurs in 2 to 12% of patients presenting with suspected dementia. In some cases CNS toxicity occurs in a dose-dependent manner, often as a result of interference with neurotransmitter function. Drug-induced delirium can also occur as an idiosyncratic complication. Finally, delirium may occur secondary to iatrogenic complications of drug use.
Almost any drug can cause delirium, especially in a vulnerable patient. Impaired cholinergic neurotransmission has been implicated in the pathogenesis of delirium and of Alzheimer’s disease. Anticholinergic medications are important causes of acute and chronic confusional states. Nevertheless, polypharmacy with anticholinergic compounds is common, especially in nursing home residents. Recent studies have suggested that the total burden of anticholinergic drugs may determine development of delirium rather than any single agent. Also, anticholinergic effects have been identified in many drugs other than those classically thought of as having major anticholinergic effects.
Psychoactive drugs are important causes of delirium. Narcotic agents are among the most important causes of delirium in postoperative patients. Long-acting benzodiazepines are the commonest drugs to cause or exacerbate dementia. Delirium was a major complication of treatment with tricyclic antidepressants but seems less common with newer agents. Anticonvulsants can cause delirium and dementia.
Drug-induced confusion with nonpsychoactive drugs is often idiosyncratic in nature, and the diagnosis is easily missed unless clinicians maintain a high index of suspicion. Histamine H2 receptor antagonists, cardiac medications such as digoxin and β-blockers, corticosteroids, non-steroidal anti-inflammatory agents and antibiotics can all cause acute, and, less commonly, chronic confusion.
Drug-induced confusion can be prevented by avoiding polypharmacy and adhering to the saying ‘start low and go slow’. Special care is needed when prescribing for people with cognitive impairment. Early diagnosis of drug-induced confusion, and withdrawal of the offending agent or agents is essential.
Similar content being viewed by others
References
Williamson J, Chopin JM. Adverse reactions to prescribed drugs in the elderly: a multicentre study. Age Ageing 1980; 9: 73–80
Lipowski ZJ. Delirium: acute confusional state. Oxford: Oxford University Press, 1990
Rinn WE. Cognitive decline in normal aging. J Geriatr Psychiatry Neurol 1988; 1: 144–58
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC: American Psychiatric Association, 1994
O’Keeffe ST, Lavan JN. The clinical significance of delirium subtypes. Age Ageing 1999; 28: 115–9
Lindesay J, Macdonald A, Starke I. Delirium in the elderly. Oxford: Oxford University Press, 1990
Gibson GE, Blass JP, Huang H-M, et al. The cellular basis of delirium and its relevance to age-related disorder including Alzheimers disease. Int Psychogeriatr 1991; 3: 373–95
Ross CA. CNS arousal systems: possible role in delirium. Int Psychogeriatr 1991; 3: 353–71
O’Keeffe S, Lavan J. The prognostic significance of delirium in older hospital patients. J Am Geriatr Soc 1997; 45: 174–8
Levkoff SE, Evans DA, Liptzin B, et al. Delirium: the occurrence and persistence of among hospitalized elderly patients. Arch Intern Med 1992; 152: 334–40
Francis J, Martin D, Kapoor WN. A prospective study of delirium in hospitalized elderly. JAMA 1990; 263: 1097–101
Inouye SK, Viscoli CM, Horwitz RI, et al. A predictive model for delirium in hospitalized elderly medical patients based on admission characteristics. Ann Intern Med 1993; 119: 474–81
Francis J, Kapoor W. Prognosis after hospital discharge of older medical patients with delirium. J Am Geriatr Soc 1992; 40: 601–6
Ritchie K, Kildea D. Is senile dementia ‘age-related’ or ‘ageing-related’ ? Evidence from meta-analysis of dementia prevalence in the oldest old. Lancet 1995; 346: 931–4
Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408–17
Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons: predictive model and interrelationship with baseline vulnerability. JAMA 1996; 275: 852–7
George J, Bleasdale S, Singleton SJ. Causes and prognosis of delirium in elderly patients admitted to a district general hospital. Age Ageing 1997; 26: 423–7
Fishbain DA, Rotundo D. Frequency of hypoglycemic delirium in apsychiatric emergency service. Psychosomatics 1988; 29 (3): 346–8
Larson EB, Kukull WA, Buchner D, et al. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med 1987; 107: 169–73
Katz IR, Parmelee P, Brubaker K. Toxic and metabolic encephalopathies in long-term care patients. Int Psychogeriatr 1991; 3: 337–47
Starr JM, Whalley LJ. Drug induced dementia: incidence, management and prevention. Drug Saf 1994; 11: 310–17
Molchan SE, Martinez RA, Hill JL, et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res 1992; 17: 215–26
Tune LE, Bylsma FW. Benzodiazepine-induced and anticholinergic-induced delirium in the elderly. Int Psychogeriatr 1991; 3: 397–408
Blazer DG, Federspiel CF, Ray WA, et al. The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations. J Gerontol 1983; 38: 31–5
Itil T, Fink M. Anticholinergic drug induced delirium: experimental modification, quantitative EEG and behavioural correlations. J Nerv Ment Dis 1966; 143: 492–507
Nishiyama K, Momose T, Sugishita M, et al. Positron emission tomography of reversible intellectual impairment induced by long-term anticholinergic therapy. J Neurol Sci 1995; 132: 189–92
Granacher RP, Baldeserini RJ. Physostigmine: its use in acute anticholinergic syndrome with antidepressant and antiparkinsonian drugs. Arch Gen Psychiatry 1975; 32: 375–80
O’Keeffe ST, Ni Chonchubhair A. Postoperative delirium in the elderly. Br J Anaesth 1994; 73: 673–87
Sheref SE. Pattern of CNS recovery following reversal of neuromuscular blockade: comparison of atropine and glycopyrollate. Br J Anaesth 1985; 57: 188–91
Summers WK, Reich TC. Delirium after cataract surgery: review and two cases. Am J Psychiatry 1979; 136: 386–91
Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993; 3: 335–48
Cummings JL. Behavioural complications of drug treatment in Parkinson’s disease. J Am Geriatr Soc 1991; 39: 708–16
De Smet Y, Ruberg M, Serdura M, et al. Confusion, dementia and anticholinergics in Parkinsons disease. J Neurol Neurosurg Psychiatry 1982; 45: 1161–4
Katz IR, Prouty Sands L, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutinin chloride. J Am Geriatr Soc 1998; 46: 8–13
Donnellan CA, Fook L, McDonald P, et al. Oxybutinin and cognitive dysfunction. BMJ 1997; 315: 1363–4
Nebes RD, Pollock BG, Mulsant BH, et al. Low-level serum anticholinergicity as a source of baseline cognitive heterogeneity in geriatric depressed patients. Psychopharmacol Bull 1997; 33 (4): 715–20
Tune LE, Holland A, Folstein M, et al. Association of postoperative delirium with raised serum levels of anti-cholinergic drugs. Lancet 1981; II: 651–2
Tollefsen GD, Montague-Clouse J, Lancaster SP, et al. The relationship of serum anti-cholinergic activity to mental status performance in an elderly nursing home population. J Neuropsych Clin Neurosci 1991; 3: 314–19
Flacker JM, Cummings V, Mach Jr JR, et al. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry 1998; 6: 131–41
Tune LE, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149: 1393–4
Marcantonio ER, Juarez G, Goldman L, et al. The relationship of postoperative delirium with psychoactive medications. JAMA 1994; 272: 1518–22
Schor JD, Levkoff SE. Lipsitz LA, et al. Risk factors for delirium in hospitalized elderly. JAMA 1992; 267: 827–31
Foy A, O’Connell D, Henry DD, et al. Benzodiazepine use as a cause of cognitive impairment in elderly hospital patients. J Gerontol 1995; 50: M99–106
Egbert AM, Parks LH, Short LM, et al. Randomized trial of postoperative patient-controlled analgesia vs intramuscular narcotics in frail elderly men. Arch Intern Med 1990; 150: 1897–903
Miller RR, Jick H. Clinical effects of meperidine in hospitalized medical patients. J Clin Pharmacol 1978; 18: 180–9
Eisendrath SJ, Goldman B, Douglas J, et al. Meperidine-induced delirium. Am J Psychiatry 1987 144: 1062–5
Schmidt LG, Grohmann R, Strauss A, et al. Epidemiology of toxic delirium due to psychotropic drugs in hospital. Compr Psychiatry 1987; 28: 242–9
Snyder SH, Yamamura HI. Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 1977; 34: 236–9
Ravena-Springer R, Dolberg OT, Hirshmann S, et al. Delirium in elderly patients treated with risperidone: a report of three cases. J Clin Psychopharmacol 1998; 18: 171–2
Levenson JL. Neuroleptic malignant syndrome. N Engl J Med 1985; 313: 163–6
Finucane P, Price C, Ghose K. Neuroleptic malignant syndrome in an elderly patient. BMJ 1988; 296: 14–18
McShane RN, Keene J, Gedling K, et al. Do neuroleptics hasten cognitive decline in dementia? BMJ 1997; 314: 266–70
Bush DF, Liss CL, Morton A. An open multicentre long-term treatment evaluation of sinemet CR. Neurology 1989; 39 Suppl. 2: 101–4
Lieberman AN, Goldstein M, Gopinathan G, et al. Further studies with pergolide in Parkinsons disease. Neurology 1982; 32: 1181–4
Kurlan R, Miller C, Levy R, et al. Long term experience with pergolide treatment of advanced parkinsonism. Neurology 1985; 35: 738–42
Lieberman AN, Goldstein M, Gopinathan G, et al. D-1 and D-2 agonists in Parkinsons disease. Can J Neurol Sci 1987; 14: 466–73
Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982; 139: 494–7
Burton K, Larsen A, Robinson RG, et al. Parkinsons disease: a comparison of mesulergine and bromocriptine. Neurology 1985; 35: 1205–8
Jankovic J, Orman J, Janssen B. Placebo-controlled study of mesulergine in Parkinsons disease. Neurology 1985; 35: 161–5
Knegtering H, Eijck M, Huijsman A. Effects of antidepressants on cognitive functioning of elderly patients: a review. Drugs Aging 1994; 5: 192–9
Grohmann R, Ströbel C, Rüther E, et al. Adverse psychic reactions to psychotropic drugs: a report from the AMUP study. Pharmacopsychiatry 1993; 3: 84–93
Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990; 2: 88–95
Branconnier RJ, Cole JO. Effects of acute administration of trazadone and amitryptiline on cognition, cardiovascular function and salivation in the normal geriatric subject. J Clin Psychopharmacol 1986; 1 Suppl. 6: 825–8
Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994; 1: 18–46
Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995; 13: 94–104
Woo MH, Smythe MA. Association of SIADH with selective serotonin reuptake inhibitors. Ann Pharmacother 1997; 31: 108–10
Smith SJ, Kocen RS. A Creutzfeldt-Jakob like syndrome due to lithium toxicity. J Neurol Neurosurg Psychiatry 1988; 51: 120–3
Foster JR, Gershell WJ, Goldfarb AI. Lithium treatment in the elderly: I. Clinical usage. J Gerontol 1977; 32: 299–302
Brown AS, Rosen J. Lithium-induced delirium with therapeutic serum lithium levels: a case report. J Geriatr Psychiatry Neurol 1992; 5: 53–5
Trimble MR. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987; 28 Suppl. 3: S37–45
Aldenkamp AP, Vermeulen J. Phenytoin and carbamazepine: differential effects on cognitive function. Seizure 1995; 4: 95–104
Rosen JA. Dilantin dementia [letter]. Trans Am Neurol Assoc 1966; 93: 273
Brown CG, Kaminsky MJ, Feroli Jr ER, et al. Delirium with phenytoin and disulfiram administration. Ann Emerg Med 1983; 12: 310–13
Zaccara C, Campostrini R, Paganini M, et al. Long-term treatment with sodium valproate. Ther Drug Monit 1987; 9: 34–40
Cantó TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med 1991; 114: 1027–34
Picotte-Prillmayer D, DiMaggio JR, Baile WE. H2 blocker delirium. Psychosomatics 1995; 36: 74–7
Fireman Z. Central nervous system side effects after proton pump inhibitor treatment. J Clin Gastroenterol 1997; 4: 718–22
Das AF, Freston JW, Jacobs J, et al. An evaluation of safety in 37,252 patients treated with cimetidine or ranitidine. Intern Med 1990; 11: 3–14
Porter JB, Beard K, Walker AM, et al. Intensive hospital monitoring study of intravenous cimetidine. Arch Intern Med 1986; 146: 2237–9
Kowalsky SF, Andritz MB, Calvert JF, et al. Aprospective evaluation of cimetidine drug use. Hosp Pharm 1989; 24: 105–8
Schentag JJ, Cerra FB, Calleri G, et al. Pharmacokinetic and clinical studies in patients with cimetidine-induced mental confusion. Lancet 1979; I: 117–81
Cerra FB, Schentag JJ, McMillen M, et al. Mental status, the intensive care unit and cimetidine. Ann Surg 1982; 196: 565–70
Slugg PH, Haug MT, Pippenger CE. Ranitidine pharmacokinetics and adverse central nervous system reactions. Arch Intern Med 1992; 152: 2325–9
Kimelblatt BJ, Cerra FB, Calleri G, et al. Dose and serum concentration relationships in cimetidine-associated mental confusion. Gastroenterology 1980; 78: 791–5
Jenike MA, Levy JC. Physostigmine reversal of cimetidine-induced delirium and agitation. J Clin Psychopharmacol 1983; 3: 43–4
Mogelnicki SR, Waller JL, Finlayson DC. Physostigmine reversal of cimetidine-induced mental confusion. JAMA 1979; 241: 826–7
McDonnell Cooke D. The use of central nervous system manifestations in the early detection of digitalis toxicity. Heart Lung 1993; 22: 477–81
Lely AH, Van Enter JC. Non-cardiac symptoms of digitalis intoxication. Am Heart J 1972; 83: 149–52
Eisendrath SJ, Sweeney MA. Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations. Am J Psychiatry 1987; 144: 506–7
Deleu D, Schmedding E. Acute psychosis as idiosyncratic reaction to quinidine: report of two cases. BMJ 1987; 294: 1001–2
Jacobson FM, Sack DA, James SP. Delirium induced by verapamil [letter]. Am J Psychiatry 1990; 144: 248
Gillman MNA, Sandyk R. Reversal of captopril-induced psychosis with naloxone [letter]. Am J Psychiatry 1988; 142: 270
Trohman RG, Castellanos D, Castellanos A, et al. Amiodarone-induced delirium. Ann Intern Med 1988; 108: 68–9
Pfeifer HJ, Greenblatt DJ, Koch-Weiser J. Clinical use and toxicity of intravenous lidocaine (a report from the Boston Collaborative Drug Surveillance Program). Am Heart J 1978; 92: 168–73
Saravay SM, Marke J, Steinburg MD, et al. ‘Doom anxiety’ and delirium in lidocaine toxicity. Am J Psychiatry 1987; 144: 159–63
Dimsdale JE, Newton RP, Joist T. Neuropsychological side effects of beta-blockers. Arch Intern Med 1989; 149: 514–25
Rogers TK, Bowman CE. Cognitive impairment associated with beta-blockade in the elderly. Postgrad Med J 1990; 66: 1050–2
Fisher CM. Amnestic syndrome associated with propranolol toxicity: a case report. Clin Neuropharmacol 1992; 15: 397–403
Nygaard HA, Hovding G. Adverse effects of local use of beta blockers in glaucoma. Tidsskr Nor Laegeforen 1997; 117: 2019–21
Paykel ES, Fleminger R, Watson JP. Psychiatric side effects of antihypertensive drugs other than reserpine. J Clin Psychopharmacol 1982; 2: 14–39
Patten SB, Love EJ. Neuropsychiatric adverse drug reactions: passive reports to health and welfare Canada’s adverse drug reaction database (1965-present). Int J Psychiatry Med 1994; 24: 145–62
Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dose. Clin Pharmacol Ther 1972; 13: 694–8
Varney NR, Alexander B, Maclndoe JH. Reversible steroid dementia in patient without steroid psychosis. J Nerv Ment Dis 1980; 168: 753–7
O’Keeffe S, Devlin JG. Delirium and the dexamethasone suppression test in the elderly. Neuropsychobiology 1994; 30: 153–6
Lupien S, Lecours AR, Lussier I, et al. Basal Cortisol levels and cognitive decline in human aging. J Neurosci 1994; 14: 2893–903
Sapolsky R. Glucocorticoids, stress and exacerbation of excitotoxic neuron death. Semin Neurosci 1994; 6: 323–31
Grigor RR, Spitz PW, Furst DE, et al. Salicylate toxicity in elderly patients with rheumatoid arthritis. J Rheumatol 1987; 14: 60–6
Steele TE, Morton WA. Salicylate induced delirium. Psychosomatics 1986; 27: 455–6
Carney MPW. Paranoid psychosis with indomethacin. BMJ 1977; 2: 994–5
Schwartz JI, Moura RJ. Severe depersonalization and anxiety associated with indomethacin. South Med J 1983; 76: 679–80
Thornton T. Delirium associated with sulindac. JAMA 1980; 243: 1630–1
Kruis R, Barger R. Paranoid psychosis with sulindac [letter]. JAMA 1980; 243: 1420
Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum 1982; 25: 1013–15
Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med 1984; 101: 92–104
Schliamser SE, Cars O, Norrby SR. Neurotoxicity of betalactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother 1991; 27: 405–25
Nicholls PJN. Neurotoxicity of penicillin. J Antimicrob Chemother 1980; 6: 161–5
Downham TF, Cawley RA, Salley SO, et al. Systemic toxic reactions to procaine penicillin G. Sex Transm Dis 1978; 5: 4–9
Slaker RA, Danielson B. Neurotoxicity associated with ceftazidime therapy in geriatric patients with renal dysfunction. Pharmacotherapy 1991; 4: 351–2
Thomas RJ, Reagan DR. Association of a Tourette-like syndrome with ofloxacin. Ann Pharmacother 1996; 30: 138–41
Andrejak M, Schmit JL, Tondriaux A, et al. Neurologic side effects of fluoroquinolones. Therapie 1992; 47: 415–18
Keller H. Comparison of the adverse effect profile of different substances such as penicillins, tetracyclines, sulfonamides and quinolones. Infection 1991; 19 Suppl. 1: S19–24
Antoniadis A, Múller WE, Wollert U. Benzodiazepine receptor interactions may be involved in the neurotoxicity of various penicillin derivatives. Ann Neurol 1980; 8: 71–3
Tombaugh TN, Mclntyre NJ. The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc 1992; 40: 922–35
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moore, A.R., O’Keeffe, S.T. Drug-Induced Cognitive Impairment in the Elderly. Drugs & Aging 15, 15–28 (1999). https://doi.org/10.2165/00002512-199915010-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-199915010-00002